For questions about Gamifant or the ordering process, connect with a Sobi Health Systems Director today.

Contact Sobi Now
Indication and Usage

Gamifant® (emapalumab-lzsg) is an IFNγ–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

Indication and Usage

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

Important Safety Information

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have a positive purified protein derivative (PPD) test result or positive IFNγ release assay.

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

Patients should be administered prophylaxis for herpes zoster, Pneumocystis jirovecii, and fungal infections prior to Gamifant administration.

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

Infusion-Related Reactions

Infusion-related reactions, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

Adverse Reactions

In the pivotal trial, the most commonly reported adverse reactions (≥10%) for Gamifant included infection (56%), hypertension (41%), infusion-related reactions (27%), pyrexia (24%), hypokalemia (15%), constipation (15%), rash (12%), abdominal pain (12%), CMV infection (12%), diarrhea (12%), lymphocytosis (12%), cough (12%), irritability (12%), tachycardia (12%), and tachypnea (12%).

Additional selected adverse reactions (all grades) that were reported in less than 10% of patients treated with Gamifant included vomiting, acute kidney injury, asthenia, bradycardia, dyspnea, gastrointestinal hemorrhage, epistaxis, and peripheral edema.

Please see full Prescribing Information for Gamifant.

You may also contact Sobi at medinfo.us@sobi.com or 866-773-5274.

References

  1. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.
  2. Sepulveda F, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017; 49:20-26. http://dx.doi.org/10.1016/j.coi.2017.08.004.
  3. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052. doi: https://doi.org/10.1182/blood-2011-03-278127.
  4. Lehmberg K, Nichols KE, Henter J-I, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica. 2015:100(8):997-1004.
  5. Marsh RA, Haddad E. How I treat primary haemophagocytic lymphohistiocytosis. Br J Haematol. 2018;182(2):185-199. doi: 10.1111/bjh.15274.
  6. Gamifant [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB.

Calculate how much Gamifant your patient needs

Icon of a digital scale

enter Patient Weight

Enter your patient’s weight, ideally on the same day as the infusion.

weight in kg

Icon of three test tubes with varying volumes of liquid

select dose Strength

Icon of a vial and an infusion bag

Infusion Concentration*

Icon of a partially full syringe

GAMIFANT NEEDED

--
mg
--
mL

Patient weight (-- kg) x Dose strength (-- mg/kg) = Gamifant needed (-- mg)

Gamifant needed (-- mg) / Gamifant concentration (-- mg/mL) = Gamifant needed (-- mL)

Icon of a partially full infusion bag

INFUSION VOLUME
(GAMIFANT + DILUENT)

--
mL

Dose Strength (-- mg/kg) / Infusion concentration (-- mg/mL) x Patient weight (-- kg)

Gamifant is available in 2 mL, 10 mL, and 20 mL vials. Please reach out to your Health Systems Director for information about pricing.

*In cases where patient condition requires restriction of total infusion volume, higher concentrations of infusion solution than those recommended can be used as long as the final concentration of infusion solution remains ≤2.5 mg/mL. Do not dilute product to less than 0.25 mg/mL.
 

Click here to learn more about the required infusion supplies.
 

DOWNLOAD OUR DOSING AND ADMINISTRATION GUIDE